噻托溴铵治疗慢性阻塞性肺疾病作用机制研究进展

噻托溴铵是一种新型长效抗胆碱类药物,是目前第一个能每日用药1次的吸人性药物,能高度选择性作用于胆碱M1和M3受体,表现出强大的支气管扩张作用,吸入一次疗效持续24 h以上.临床实验结果表明该药对中、重度慢性阻塞性肺疾病具有良好疗效,与其他常用抗胆碱能药物和β2受体激动剂相比较,噻托溴铵可显著改善肺功能、减少急性发作和改善生命质量,耐受性和安全性较好,主要不良反应为口干.

Tiotropium bromide treatment mechanism and research progress of chronic obstructive pulmonary disease

Tiotropium bromide is a new long-acting anticholinergie drug, is the first to use a daily administration of the inhaled drug. It has highly selective role in the cholinergie receptor M1 and M3 ,showing strong bronchial expansion. In several clinical studies,tiotropium bromide administered once daily has shown its efficacy in the treatment of patients who have moderate to very severe chronic obstructive pulmonary disease,and is superior to other commonly used anti-eholinergie drugs and β2 agonist, tiotropium bromide significantly improves lung function,reduces acute exacerbation frequency and betters the quality of life, and also is well-tolerated and safe to patients. A major side effect is reported as dryness of the mouth.